Xilio Therapeutics, Inc.
XLO
$8.46
-$0.05-0.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 39.84% | 6.87% | 14.21% | 23.47% | 23.77% |
| Total Depreciation and Amortization | -6.27% | -7.16% | -9.07% | -7.92% | -13.47% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -47.52% | 238.48% | 15.86% | -18.72% | -14.65% |
| Change in Net Operating Assets | -20.95% | -54.87% | -15.98% | 778.42% | 2,016.89% |
| Cash from Operations | 72.84% | 2.82% | 23.16% | 139.17% | 73.22% |
| Capital Expenditure | -1,338.89% | -1,330.00% | -1,985.71% | 81.65% | 92.59% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1,338.89% | -1,330.00% | -1,985.71% | 81.65% | 92.59% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | 99.90% | 99.67% | 49.91% |
| Issuance of Common Stock | 169.43% | -46.47% | -46.46% | 633.97% | 16,027.72% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 200.64% | 210.49% | 252.62% | 946.32% | 545.74% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 662.98% | 2,428.60% | 19,609.21% | 193.15% | 114.25% |